Press Release Archive

 
May 16, 2014 - Pfizer To Submit Palbociclib New Drug Application With FDA Based On Final Results Of PALOMA-1

Pfizer Inc. today announced that it will submit a New Drug Application (NDA) with the United States Food and Drug Administration (FDA) for palbociclib, combined with letrozole, as first-line systemic treatment of post-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer.

 
May 14, 2014 - American College of Physicians, CECity, and Pfizer collaborate to increase adult immunization rates

The American College of Physicians (ACP), CECity, and Pfizer Inc. (NYSE:PFE) today announced a new initiative designed to increase adult immunization rates by assisting physicians and other health care providers in strongly recommending appropriate vaccination and tracking adult immunization rates for quality measurement and improvement. The three organizations made the announcement during the annual National Adult Influenza and Immunization Summit meeting being held May 13-15 in Atlanta.

 
May 13, 2014 - STATEMENT FROM PFIZER INC. (“PFIZER”)

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

13 MAY 2014

 
May 12, 2014 - Pfizer Prices $4.5 Billion Debt Offering

 

Pfizer Inc. (NYSE:PFE) today announced the pricing of a debt offering consisting of five tranches of notes:

 
May 9, 2014 - Pfizer Announces Positive Phase 2 Study Results for Investigational Meningococcal B Vaccine

Pfizer Inc. (NYSE:PFE) announced today the results from two Phase 2 studies of bivalent rLP2086, Pfizer’s recombinant vaccine candidate, currently under development for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 to 25 year olds. In both studies, bivalent rLP2086 was observed to generate bactericidal responses, a measurement of functional immune response, against diverse meningococcal serogroup B test strains following either two or three doses

 
May 5, 2014 - Pfizer Reports First-Quarter 2014 Results
 
May 2, 2014 - Pfizer Sends Letter to Rt Hon David Cameron MP Regarding Commitments If Proposed Combination with AstraZeneca is Completed

Pfizer Chairman and Chief Executive Officer, Ian Read, today sent the following letter to the Rt Hon David Cameron MP, with respect to Pfizer’s commitment to the U.K. and its life sciences agenda following the company’s proposal made to AstraZeneca on May 2, 2014.

 
May 2, 2014 - Pfizer Confirms Delivery of Increased Proposal to AstraZeneca

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

 
May 1, 2014 - ALO-02 Demonstrates Significant Difference In Pain Scores In Chronic Low Back Pain Patients And Lower Abuse Potential Compared To Immediate-Release Oxycodone In Recreational Opioid Users

Pfizer Inc. (NYSE:PFE) presented results today from three pivotal studies of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules).

 
April 28, 2014 - Pfizer Invites Investors, Analysts And Media To Join Conference Calls Discussing Possible Combination With AstraZeneca

 

Pfizer Inc. will hold analyst and investor calls to discuss its continuing interest in a possible merger transaction with AstraZeneca Plc. at 8:30 AM EDT (1:30 PM GMT) today, April 28, 2014.

 
April 28, 2014 - Pfizer Confirms Prior Discussions with AstraZeneca Regarding a Possible Combination and Its Continuing Interest in a Possible Merger Transaction

STATEMENT FROM PFIZER INC. (“PFIZER”)

POSSIBLE OFFER FOR ASTRAZENECA PLC (“ASTRAZENECA”)

 
April 24, 2014 - Pfizer Hosts Annual Meeting of Shareholders Declares 26-Cent Second-Quarter 2014 Dividend

The board of directors of Pfizer Inc. today declared a 26-cent second-quarter 2014 dividend on the company’s common stock, payable June 3, 2014, to shareholders of record at the close of business on May 9, 2014. The second-quarter 2014 cash dividend will be the 302nd consecutive quarterly dividend paid by Pfizer.

 
April 22, 2014 - Pfizer Announces Positive Top-Line Results From Two Phase 3 Trials Of Tofacitinib In Adults With Moderate-to-Severe Chronic Plaque Psoriasis

Pfizer Inc. (NYSE:PFE) announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis. The OPT Pivotal #1 and OPT Pivotal #2 studies showed that tofacitinib, as a 5 mg or a 10 mg dose taken as a pill twice-daily, met the primary efficacy endpoints of statistically significant superiority over placebo at Week 16 in the proportion of subjects achieving a Physician’s Global Assessment response of “clear” or “almost clear,” and the proportion of subjects achieving at least a 75% reduction in Psoriasis Area and Severity Index, two commonly used measures of efficacy in psoriasis.

 
April 18, 2014 - Pfizer Invites Public To Listen To Webcast Of April 24 Annual Meeting Of Shareholders

Pfizer Inc. invites investors and the general public to listen to a webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Eastern Daylight Time) on Thursday, April 24.

 
April 14, 2014 - Advil® Relief in Action and Josh Duhamel Celebrate National Volunteer Week with Points of Light & Kick Off a Nationwide "Relief" Tour

Pfizer Consumer Healthcare, makers of Advil® and a unit of Pfizer Inc. (NYSE:PFE), is teaming up with actor and active volunteer Josh Duhamel for the Advil® Relief in Action campaign. Through the#ReliefinAction Pledge on Facebook and a Mobile Relief Center tour making approximately 100 stops throughout the country, Advil® will relieve the tough physical pain that can come with actively volunteering.

 
April 6, 2014 - Pfizer’s Novel CDK 4/6 Inhibitor Palbociclib plus Letrozole Significantly Prolonged Progression-Free Survival in Patients with Advanced Breast Cancer

Pfizer Inc. today announced detailed results from the PALOMA-1 study, a randomized Phase 2 study of palbociclib (PD-0332991) in combination with letrozole.

 
March 28, 2014 - Pfizer Statement on U.S. FDA Approval of Over-the-Counter Nexium® 24HR

Today the U.S. Food and Drug Administration (FDA) approved over-the-counter Nexium® 24HR (esomeprazole 20mg) marking a key step towards providing those who suffer from frequent heartburn broader access to a brand doctors and patients have trusted for years.

 
March 27, 2014 - In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control 1

Bristol-Myers Squibb Company (NYSE: BMY) andPfizer Inc. (NYSE: PFE) today announced the results of a pre-specified subanalysis of the Phase 3 ARISTOTLE trial that assessed the effect of blood pressure control on outcomes as well as the treatment effect of Eliquis (apixaban) compared to warfarin according to blood pressure control.1 The results showed that poor blood pressure control was associated with a substantially higher risk of stroke or systemic embolism, independent of Eliquis or warfarin treatment. However, this subanalysis found consistent results for Eliquisversus warfarin in reducing the risk of stroke, regardless of blood pressure control.1 These data will be presented Saturday, March 29, at the American College of Cardiology’s (ACC) 63rd Annual Scientific Session in Washington, D.C.

 
March 27, 2014 - Bococizumab (RN316) Significantly Reduced LDL Cholesterol In Statin-Treated Adults With High Cholesterol In A Phase 2b Study

Pfizer Inc. (NYSE: PFE) today announced the Phase 2b results of a 24 week, randomized, placebo-controlled, dose-ranging study of investigational bococizumab, the proposed generic name for RN316. Statin treated patients with high cholesterol were randomized to various doses of either bococizumab twice or once monthly subcutaneous administration or placebo. The study met its primary endpoint across all doses, showing that bococizumab significantly reduced low density lipoprotein cholesterol (LDL-C) from baseline compared to placebo in adults with high cholesterol also taking statin therapy.1 The percentage of patients reporting adverse events or serious adverse events was similar across placebo- and bococizumab-treatment groups. The Phase 3 program for bococizumab was initiated in October 2013.

Pages

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

 

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

pdf

If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.

Current Stock Price

.
.
%Change . 52 Wk. High .
Day High . 52 Wk. Low .
Day Low . Mkt. Cap(Mil) .
Open .
Prev Close . Symbol .
Vol. . Exchange .

Online Pfizer Press Kit

Our press kit provides information that might help you write stories or simply find out more about Pfizer.